A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the Effects of SUL-238 on High Energy Phosphates With Magnetic Resonance Spectroscopy (????P-MRS) in Patients With Early, Untreated Parkinson's Disease ("SHEPHERD" STUDY)
Latest Information Update: 13 Jan 2026
At a glance
- Drugs SUL 238 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SHEPHERD
- Sponsors Gen Ilac
Most Recent Events
- 13 Jan 2026 New trial record